Docetaxel (Tautax) in the treatment of hormone-refractory prostate cancer
Purpose. Evaluate efficacy and portability of the combination of the drugs Tautax (docetaxel) with a dose of 75mg/m2 1 time per 21 days and prednisolone — 10 mg per 24 h in hormone-refractory prostate cancer (HRPC) patients. Methods. Patients with verified HRPC were included in the study. Patients w...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-02-01
|
| Series: | Onkourologiâ |
| Online Access: | https://oncourology.abvpress.ru/oncur/article/view/1105 |